Casebia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Casebia Therapeutics's estimated annual revenue is currently $310k per year.
- Casebia Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Casebia Therapeutics has 2 Employees.
- Casebia Therapeutics grew their employee count by -50% last year.
Casebia Therapeutics's People
| Name | Title | Email/Phone |
|---|
Casebia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Casebia Therapeutics?
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
keywords:N/A
N/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Casebia Therapeutics News
Before 7joining Exo Therapeutics, Schneider was SVP of finance at Casebia Therapeutics, LLC. Before Casebia, he held senior finance...
Schneider was Senior Vice President, Finance at Casebia Therapeutics, LLC. Before joining Casebia, he held senior finance positions at Aegerion...
Prior to joining Exo in 2020, he was SVP of finance at Casebia Therapeutics. Release. Evidence of its commitment to clinical progress,...
... with small startups, including its 2016 Casebia Therapeutics, formed by Bayer and CRISPR Therapeutics, which aims to cure blood disorders ...
Thirteen biopharma companies, including Sangamo Therapeutics and ... James Burns, CEO of Casebia Therapeutics, one of the co-signers, ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.3M | 2 | 0% | N/A |
#2 | $0M | 2 | -60% | $44.2M |
#3 | $0.1M | 2 | 100% | $1.7M |
#4 | $0.1M | 2 | 0% | N/A |
#5 | $0.2M | 2 | -50% | N/A |